Google+ Facebook Twitter Twitter

Tech news: November

This month's top tech news stories

SARS-CoV-2 solutions

LGC’s SeraCare has expanded its line of SARS-CoV-2 quality solutions to include products designed for use with multiplexed molecular assays that can detect SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV).

The AccuPlex SARS-CoV-2, Flu A/B and RSV Verification Panel is optimised for assay verification at installation by documenting test performance along the assay’s range. 

This enables labs to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency. 

The AccuPlex SARS-CoV-2, Flu A/B and RSV Reference Material Kit measures day-to-day assay performance, providing a positive and a negative reference solution.

Ex Vivo Therapies

Mogrify, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has announced the introduction of EpiMOGRIFY. 

The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.

It is an extension of the company’s proprietary direct cellular conversion technology MOGRIFY.

Axol Bioscience
MEA Screening

Axol Bioscience has expanded its service offering with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells.

The new services have been developed to support pre-clinical research by optimising hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.

Download PDF

Related Articles

Tech news: April

This month's top tech news stories

Study advances field of precision medicine

A new method of quickly mapping the genome of single cells, while also clarifying the spatial position of the cells within the body, has been revealed.

DNA in urine for cancer detection

A team of scientists has found that DNA fragments in the urine are not degraded at random or too short to provide any meaningful information.